关键词: 低氧诱导因子脯氨酸羟化酶抑制剂, 罗沙司他, 中枢性甲状腺功能减退, 血液透析, 肾性贫血

Abstract:

Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of oral medications for treating renal anemia, but adverse drug events have been reported both in China and internationally in recent years. This article reports two cases of reversible central hypothyroidism following the administration of the HIF-PHI roxadustat in patients undergoing regular hemodialysis with end-stage renal disease. Both patients gradually developed non-specific discomfort symptoms after one year of oral roxadustat treatment. Laboratory tests revealed abnormal thyroid function, while cranial magnetic resonance imaging showed no abnormalities. After discontinuation of roxadustat, thyroid function returned to normal and the symptoms resolved. These two cases suggest that it is necessary to monitor thyroid function in patients receiving oral roxadustat for renal anemia.

Key words: Hypoxia-inducible factor prolyl hydroxylase inhibitor, Roxadustat, Central hypothyroidism, Hemodialysis, Renal anemia